Zydus And Synthon Sign US Ibrance Generic Deal With Potential Exclusivity
Synthon And Pfizer Settle US Patent Infringement Claims Over $3.1bn Palbociclib Brand
Zydus and Synthon’s entry into a high-value collaboration on palbociclib tablets is amped up with a paragraph IV certification, which may lead to a 180-day market exclusivity.
You may also be interested in...
Plus alliances involving Xyphos/Kelonia, Nippon Shinyaku/Vicor, Telix/QSAM, Nicox/Kowa, Kyowa Kirin/BridgeBio, as well as deals in brief.
Zydus is developing a novel ADC, one of the most challenging but rewarding treatment modalities today as others in the class like Kadcyla and Enhertu prove. The Indian firm's managing director spoke to Scrip about R&D efforts, recent policy moves and gains from making the world’s first approved recombinant plasmid DNA vaccine.
Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.